Allianz reports financial performance and sustainability achievements for 2024

Oliver Bäte Chairman of the Board of Management of Allianz SE (CEO) Allianz SE
Oliver Bäte Chairman of the Board of Management of Allianz SE (CEO) - Allianz SE
0Comments

The Allianz Group operates as a major insurer and asset manager, serving private and corporate clients in almost 70 countries. The company provides a wide array of insurance products, including property, life, health, assistance services, credit insurance, and global business insurance.

Allianz manages approximately 749 billion euros for its insurance customers as of June 30, 2025. In addition to these assets, its subsidiaries PIMCO and Allianz Global Investors oversee about 1.8 trillion euros in third-party assets.

The group has incorporated ecological and social criteria into its business practices and investment decisions. This approach has positioned Allianz among the top companies in the Dow Jones Sustainability Index.

In 2024, Allianz employed more than 156,000 people worldwide. That year, the company reported a total business volume of 179.8 billion euros and an operating profit of 16.0 billion euros.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.